Kenvue Inc. (NYSE:KVUE) Shares Purchased by Bard Financial Services Inc.

Bard Financial Services Inc. lifted its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 16.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 126,290 shares of the company's stock after acquiring an additional 17,500 shares during the quarter. Bard Financial Services Inc.'s holdings in Kenvue were worth $3,028,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in KVUE. SRS Capital Advisors Inc. raised its holdings in shares of Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after purchasing an additional 571 shares in the last quarter. Asset Planning Inc purchased a new position in Kenvue during the fourth quarter valued at approximately $42,000. Clarity Asset Management Inc. bought a new position in Kenvue in the fourth quarter worth approximately $45,000. SBI Securities Co. Ltd. purchased a new stake in Kenvue during the fourth quarter worth $46,000. Finally, Deseret Mutual Benefit Administrators boosted its position in Kenvue by 29.0% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock valued at $54,000 after acquiring an additional 568 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Up 0.8%

Shares of KVUE traded up $0.18 during mid-day trading on Thursday, hitting $22.03. 15,065,405 shares of the company traded hands, compared to its average volume of 16,361,186. The company has a market capitalization of $42.27 billion, a PE ratio of 41.57, a price-to-earnings-growth ratio of 2.62 and a beta of 0.98. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The business has a 50 day moving average of $23.02 and a 200 day moving average of $22.54. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. The business had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Kenvue's revenue for the quarter was down 3.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.28 EPS. Equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.72%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue's payout ratio is 149.09%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Canaccord Genuity Group boosted their price target on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Piper Sandler lifted their target price on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Evercore ISI started coverage on shares of Kenvue in a report on Monday, March 24th. They issued an "in-line" rating and a $25.00 target price for the company. Barclays increased their price target on shares of Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. Finally, Redburn Atlantic started coverage on shares of Kenvue in a research report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective on the stock. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, Kenvue currently has a consensus rating of "Hold" and a consensus price target of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.